Publications by authors named "P Lepelley"
Article Synopsis
- ABCB1 is an ATP binding cassette transporter that is linked to poor outcomes in acute myeloid leukemia (AML) patients undergoing chemotherapy, but its exact role in drug resistance is not fully understood.
- In a study of 321 AML patients, high ABCB1 activity correlated with lower white blood cell counts and specific gene expressions, indicating a potential relationship with the disease's severity.
- However, ABCB1 activity did not directly cause drug resistance to treatment, and inhibiting ABCB1 did not improve patient outcomes, suggesting it may just be a characteristic of high-risk AML rather than a direct cause of resistance.
Article Synopsis
- The study examines the use of minimal residual disease (MRD) assessment in acute myeloblastic leukemia as a prognostic tool, utilizing multiparameter flow cytometry (MFC) to track leukemia-specific immunophenotypes for better patient outcomes.
- Conducted across 10 different MFC centers with 276 patients, it established a standardized method for analyzing MRD using specific immunophenotypic markers, leading to consistent results in monitoring disease status.
- Findings reveal that negative MRD levels significantly correlate with better survival rates, while any positive MRD levels indicate poorer outcomes, regardless of cytogenetic risk factors, thus proving MRD's critical role in patient stratification.
In core binding factor (CBF) acute myeloid leukaemia (AML), realtime quantitative PCR is useful to quantify the fusion transcript ratio (CBFβ-MYH11 and AML1-ETO, in case of inv(16) and t(8;21) respectively) in peripheral blood and bone marrow during the courses of chemotherapy, in order to monitor minimal residual disease (MRD). In two cases of CBF AML associated with systemic mastocytosis (SM), the persistence of mast cells and the detection of a high ratio of fusion transcript, in bone marrow, during the courses of chemotherapy, led us to determine whether the mast cell component of the disease carried the same molecular alterations as leukaemic blasts. We demonstrate that sorted mast cells carried CBF abnormality.
View Article and Find Full Text PDFBackground: Flow cytometry is the sole available technique for quantification of tumor plasma-cells in plasma-cell disorders, but so far, no consensus technique has been proposed. Here, we report on a standardized, simple, robust five color flow cytometry protocol developed to characterize and quantify bone marrow tumor plasma-cells, validated in a multicenter manner.
Methods: CD36 was used to exclude red blood cell debris and erythroblasts, CD38 and CD138 to detect plasma-cells, immunoglobulin light chains, CD45, CD56, CD19, and CD117 + CD34 to simultaneously characterize abnormal plasma-cells and quantify bone marrow precursors.
Waldenström's macroglobulinemia (WM) is a B-cell disorder characterized primarily by bone marrow infiltration with lymphoplasmacytic cells, along with the presence of an IgM monoclonal gammopathy in the blood. WM remains incurable with a median of 8-year of overall survival for patients with symptomatic WM. Treatment is postponed for asymptomatic patients and progressive anemia is the most common indication for initiation of treatment.
View Article and Find Full Text PDF